Although nearly half of postmenopausal women reported having vulvovaginal symptoms (VVS), only a minority discussed their symptoms during a well-woman visit with a primary care provider or gynecologist, according to recent survey analysis.
A new study, which found that women with premature and early menopause were at increased risk of having a non-fatal cardiovascular disease event before age 60, has consequential public health and clinical implications.
A recent study describes the development of a web-based calculator that predicts the likelihood of experiencing multiple and competing morbidity outcomes over 5, 10, and 15 years.
New research explored whether midlife women with type 2 diabetes mellitus (T2DM) are at higher risk of sleep-related symptoms.
A recent study evaluated the impact of menopause on multiple sclerosis (MS), including disease activity and disability progression.
A new study aims to clarify the quantitative association between age at menopause and T2DM.
New research examines whether women who experience a heart attack, stroke or other type of cardiovascular event before age 35 have a higher risk of early menopause.
GSM can be clinically detected in up to 90% of postmenopausal women undergoing evaluation but only one-third report vulvovaginal symptoms when surveyed.
The safety and efficacy of targeting vulvovaginal tissues are the topic of this committee opinion.
Phytoestrogen use is an apparent mixed bag of effects, some good and some adverse.